Covid-19疫苗的研究与开发

N. Ekong
{"title":"Covid-19疫苗的研究与开发","authors":"N. Ekong","doi":"10.35248/2157-7560.21.S10.E001","DOIUrl":null,"url":null,"abstract":"The first generation covid-19 vaccine was expected to come by the end of 2020 or beginning of 2021. The vaccine was developed to provide immunity to the population and to reduce the spread of the infection or the virus. There are more than 5 vaccines which are developed and under the phase 3 clinical trials to test the safety, efficacy, quality and purity of vaccine. The WHO recommends that the vaccine need to show at least 50% risk reduction for causing infection and 95% efficacy in treating and curing the infected patient and100% safety rate to be approved [3].","PeriodicalId":17656,"journal":{"name":"Journal of Vaccines and Vaccination","volume":"112 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Research and Development of Covid-19 Vaccine\",\"authors\":\"N. Ekong\",\"doi\":\"10.35248/2157-7560.21.S10.E001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The first generation covid-19 vaccine was expected to come by the end of 2020 or beginning of 2021. The vaccine was developed to provide immunity to the population and to reduce the spread of the infection or the virus. There are more than 5 vaccines which are developed and under the phase 3 clinical trials to test the safety, efficacy, quality and purity of vaccine. The WHO recommends that the vaccine need to show at least 50% risk reduction for causing infection and 95% efficacy in treating and curing the infected patient and100% safety rate to be approved [3].\",\"PeriodicalId\":17656,\"journal\":{\"name\":\"Journal of Vaccines and Vaccination\",\"volume\":\"112 1\",\"pages\":\"1-1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Vaccines and Vaccination\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2157-7560.21.S10.E001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vaccines and Vaccination","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2157-7560.21.S10.E001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

第一代covid-19疫苗预计将在2020年底或2021年初问世。研制这种疫苗是为了给人群提供免疫力,减少感染或病毒的传播。目前正在开发的疫苗有5种以上,正在进行三期临床试验,以检验疫苗的安全性、有效性、质量和纯度。世卫组织建议,疫苗需要至少降低50%的感染风险,95%的治疗和治愈感染者的有效性和100%的安全性才能获得批准[3]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Research and Development of Covid-19 Vaccine
The first generation covid-19 vaccine was expected to come by the end of 2020 or beginning of 2021. The vaccine was developed to provide immunity to the population and to reduce the spread of the infection or the virus. There are more than 5 vaccines which are developed and under the phase 3 clinical trials to test the safety, efficacy, quality and purity of vaccine. The WHO recommends that the vaccine need to show at least 50% risk reduction for causing infection and 95% efficacy in treating and curing the infected patient and100% safety rate to be approved [3].
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Differential Transcription Profiling in Bone Marrow Mononuclear Cells Between Myasthenia Gravis Patients With or Without Thymoma Rapid screening for variants of concern in routine SARS-CoV-2 PCR diagnostics Mast Cells and COVID-19: a case report implicating a role of mast cell activation in the prevention and treatment of Covid-19 Evaluating Child Malnutrition in Southern Belize Using an Anthropologic Screening Tool Sero-prevalence and risk factors for sheeppox in Kordofan states in Sudan
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1